D

이연제약

102460KOSPI의약품 제조업

37.0 / 100

Reference Date: 2026-04-13

Financial Score8.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Declined 5.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Il Yeon Pharm is a specialized pharmaceutical company established in 1964, focusing on the manufacturing and sales of prescription drugs, original pharmaceuticals (e.g., CT contrast agent 'Optirey'), and bulk drugs. Its Chungju facility, certified for biopharmaceutical production and CMO services, supports new drug pipeline development through a production-platform-based R&D model. However, as of 2024, the company reported sales of 145.9 billion won, an operating loss of 30.3 billion won, and a net loss of 29.6 billion won, indicating the need for improved profitability.

Number of Employees

457people

Average Salary

76.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 14.804.0Point
PBR
0.84Industry Average 1.044.0Point

In line with industry avg

ROE
-12.60Industry Average 4.420.0Point

Well below industry avg

Debt Ratio
46.08Industry Average 11.980.0Point

3.8x industry avg (risky)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼1.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼19193.7% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -3.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 9,900Won52-week high 13,75052-week low 9,880
1-month return2.0Point

1m -5.71% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral정기주주총회결과2026-03-30
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30
  • Neutral사업보고서 (2025.12)2026-03-20
  • Neutral감사보고서제출2026-03-20